Who is sponsoring NCT05139342?

NCT05139342 is sponsored by Kliniken Beelitz GmbH.

What drugs are being tested in NCT05139342?

Interventions in NCT05139342: expiratory muscle strentgh training (EMST).

What condition does NCT05139342 study?

NCT05139342 studies Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy.

Is NCT05139342 still recruiting?

NCT05139342 is currently status unknown. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT05139342: EMST-PS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Efficacy of a Two-week EMST on Dysphagia in Parkinsonian Patients

Status unknown NA Last updated 15 June 2023

What this trial tests

NA trial testing expiratory muscle strentgh training (EMST) in Parkinson Disease in 75 participants. Status unknown.

Timeline

15 November 2021

Primary endpoint
31 August 2023

31 December 2023

Quick facts

Lead sponsor	Kliniken Beelitz GmbH
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	75
Start date	15 November 2021
Primary completion	31 August 2023
Estimated completion	31 December 2023
Sites	3 locations across Germany

Drugs / interventions tested

expiratory muscle strentgh training (EMST)

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →
Multiple System Atrophy — all drugs for Multiple System Atrophy →
Progressive Supranuclear Palsy — all drugs for Progressive Supranuclear Palsy →

Sponsor

Kliniken Beelitz GmbH

Who can join

18 and older, any sex, with Parkinson Disease or Multiple System Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an interventional therapy study designed to evaluate the efficacy of a two-week intervention, i.e. training with a specialized exhalation training device (called expiratory muscle strength training; EMST150 or EMST75; Aspire Products, Gainsville, FL) on swallowing function in patients with neurodegenerative Parkinsonian disorders. This study involves a routine endoscopic evaluation of swallowing (FEES) to diagnose dysphagia before and after the intervention. Between the two FEES, a two-week exhalation training program takes place, which the patients perform independently following instructions from a speech and lanuage pathologist. In addition demographic and disease-specific data and two questionnaires (Swallowing Disturbance Questionnaire for Parkinson's disease patients, SDQ-PD, and Swallowing specific Quality Of Life Questionnaire SWAL-QoL) are recorded.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Is Dysphagia in Multiple System Atrophy Responsive to Levodopa? Results from a Retrospective Study.
Gandor F, Berger L, Jäger V, Demmin K, et al · · 2026 · cited 2× · PMID 40940632 · DOI 10.1002/mdc3.70355
Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review.
Dunning EE, Decourt B, Zawia NH, Shill HA, et al · · 2024 · cited 2× · PMID 38743312 · DOI 10.1007/s40120-024-00614-9

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Kliniken Beelitz GmbH trials

Trials by the same sponsor.

NCT04706234 — Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05139342 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kliniken Beelitz GmbH
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05139342.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing